Addiction. Other psychoactive substance related disorders
Conditions
Interventions
Intervention 1: Intervention group: In this group of patients (n=20) will be requested to take one quetiapine (100 mg) tablets daily for 8 weeks. The quetiapine tablets will be produced in the Sanamed
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 55 Years
Inclusion criteria
Inclusion criteria: Aged 25 to 55 Patients with addiction (Evaluated by the drug abuse section of the Structured Clinical Interview for DSM-IV) Seeking for treatment Normal potassium levels and ECG of the patient before the intervention Complete informed consent
Exclusion criteria
Exclusion criteria: Unwillingness to cooperate Suicide attempts Patients with cardiovascular disorders, metabolic and neurological diseases Positive urine test for cannabis, tramadol, and methamphetamine. The patient is currently physically dependent on alcohol or sedatives. Use of medications that interact with quetiapine (such as barbiturates, glucocorticoids, rifampin, carbamazepine, ketoconazole, erythromycin, and levodopa)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Craving. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Desire for Drug Questionnaire (DDQ craving).;Blood pressure measurement. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood pressure measuring device.;Heart rate measurement. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Heart rate monitor. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mental health. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Depression Anxiety Stress Scales (DASS) questionnaire.;Sleep Quality. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI) questionnaire.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;High-density lipoprotein (HDL) cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehrdad Simani
Kashan University of Medical Sciences
Outcome results
None listed